Sana Biotechnology (SANA) Change in Accured Expenses (2020 - 2026)

Sana Biotechnology (SANA) has 7 years of Change in Accured Expenses data on file, last reported at -$7.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 20.23% year-over-year to -$7.1 million; the trailing twelve-month figure through Mar 2026 stood at -$2.9 million (up 60.63% YoY), and the FY2025 full-year result was -$4.7 million, up 43.54% from the prior year.
• Change in Accured Expenses slipped to -$7.1 million in Q1 2026, from $5.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $7.9 million in Q3 2022 to a low of -$10.3 million in Q1 2023.
• A 5-year average of -$637000.0 and a median of $167000.0 in 2023 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses tumbled 1913.17% in 2024 and surged 304.56% in 2025, its largest moves.
• Tracing SANA's Change in Accured Expenses over 5 years: stood at $2.1 million in 2022, then sank by 91.96% to $167000.0 in 2023, then plunged by 1913.17% to -$3.0 million in 2024, then jumped by 290.13% to $5.8 million in 2025, then tumbled by 223.22% to -$7.1 million in 2026.
• Business Quant data shows SANA's Change in Accured Expenses at -$7.1 million in Q1 2026, $5.8 million in Q4 2025, and $1.4 million in Q3 2025.